On World Cancer Day 4 February 2026, the UK government and NHS England published a long-awaited National Cancer Plan for England, setting out a decade-long strategy to transform how cancer is prevented, diagnosed and treated across the country. The plan, the first since 2015 and tied into the NHS’s broader 10-Year Health Plan, reflects both a stark challenge and a bold commitment. By 2035, three in four people diagnosed with cancer should survive for five years or more.
This target represents one of the most ambitious survival goals in the NHS’s history and, if successful, would translate into roughly 320,000 more lives saved over the lifetime of the strategy. The plan has been shaped by unprecedented public input, over 11,000 responses to a call for evidence, and draws on advances in science, technology and earlier detection to reset cancer services for a new era.
The new strategy places early diagnosis at the heart of its approach, recognising that catching cancer sooner remains one of the most powerful levers to improve outcomes. The plan reinforces national screening expansion, including lowering thresholds for bowel cancer tests and the full rollout of lung cancer screening by 2030. It also places greater emphasis on genomics, with more systematic access to genetic testing to identify those at heightened inherited risk and personalise treatment plans.
Prevention is framed as equally vital. Alongside traditional campaigns on tobacco, obesity and alcohol, the strategy includes landmark legislative ambitions such as the Tobacco and Vapes Bill, which prohibits the legal sale of tobacco to anyone born on or after 1 January 2009. HPV vaccination catch-ups aim to accelerate progress toward eliminating cervical cancer, while new screening and case-finding initiatives seek to spot cancers like pancreatic and liver disease earlier.
Fair access to care sits at the plan’s core. England currently lags behind comparable countries in outcomes for certain cancers, and survival rates vary significantly by region, socioeconomic status and ethnicity. The National Cancer Plan promises to reduce unwarranted variation by strengthening regional Cancer Alliances, improving diagnostic access, and boosting specialist expertise in historically underserved areas. There is also a renewed emphasis on rare and less survivable cancers, with tailored approaches designed to close stubborn outcome gaps that have persisted for decades.
On the treatment front, the strategy seeks to end the postcode lottery that has too often determined who gets cutting-edge therapies and timely care. Patients will be able to access genomic testing where clinically appropriate, broadening the scope for personalised treatments and targeted clinical trial participation. New technology, including artificial intelligence to aid detection and digital diagnostic capacity, aims to deliver faster, more accurate results while significantly expanding testing volumes, with an estimated 9.5 million additional diagnostic tests delivered annually by 2029.
The plan also promises more patient-centred support structures. From personalised cancer plans that include mental health and social care needs to neighbourhood care leads coordinating post-treatment support, the strategy reflects a shift toward care that fits more naturally around people’s lives. Digital tools, including expanded functionality in the NHS App by 2028 to manage invitations, appointments and risk profiles, further underline this modernisation.
Research and innovation are treated as engines of progress. The plan outlines six clear research challenges aimed at accelerating breakthroughs in cancer survival and positions the NHS as a global partner of choice for clinical trials, particularly for rarer cancers and historically under-represented groups. A new cancer trials accelerator and expanded integration of genomic and digital data promise faster adoption of emerging therapies and more inclusive access to potentially life-saving innovations.
Central to the strategy are improvements in cancer waiting times, an area where performance has lagged in recent years. The plan commits to meeting all key NHS cancer waiting time standards by March 2029, including ensuring more patients start treatment within the critical 62-day target from urgent referral.
Yet questions remain about how the ambitious goals will translate into practice. Implementation, funding, workforce capacity and equitable rollout are all central to whether this plan can truly achieve its aspirations. Critics point to the need for cohesive delivery mechanisms and sustained investment to avoid promises outpacing real-world progress.
A Turning Point in National Cancer Policy
England’s National Cancer Plan for 2026–2035 represents a strategic reset, from prevention and early detection to personalised treatment, research integration and patient experience. Its success will be measured not just in survival statistics but in real shifts in how cancer is understood, managed and overcome across communities. For patients, clinicians and policymakers alike, the next decade may be defined by how effectively these ambitions are delivered into everyday care.